248 related articles for article (PubMed ID: 11546768)
1. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.
Mao Y; Desai SD; Ting CY; Hwang J; Liu LF
J Biol Chem; 2001 Nov; 276(44):40652-8. PubMed ID: 11546768
[TBL] [Abstract][Full Text] [Related]
2. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
3. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
4. The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1).
Isik S; Sano K; Tsutsui K; Seki M; Enomoto T; Saitoh H; Tsutsui K
FEBS Lett; 2003 Jul; 546(2-3):374-8. PubMed ID: 12832072
[TBL] [Abstract][Full Text] [Related]
5. Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity.
Sciascia N; Wu W; Zong D; Sun Y; Wong N; John S; Wangsa D; Ried T; Bunting SF; Pommier Y; Nussenzweig A
Elife; 2020 Feb; 9():. PubMed ID: 32057297
[TBL] [Abstract][Full Text] [Related]
6. SCF
Shu J; Cui D; Ma Y; Xiong X; Sun Y; Zhao Y
Oncogenesis; 2020 Feb; 9(2):8. PubMed ID: 32015321
[TBL] [Abstract][Full Text] [Related]
7. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
8. The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target.
Alchanati I; Teicher C; Cohen G; Shemesh V; Barr HM; Nakache P; Ben-Avraham D; Idelevich A; Angel I; Livnah N; Tuvia S; Reiss Y; Taglicht D; Erez O
PLoS One; 2009 Dec; 4(12):e8104. PubMed ID: 19956605
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
10. The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Xiao H; Goodrich DW
Oncogene; 2005 Dec; 24(55):8105-13. PubMed ID: 16091739
[TBL] [Abstract][Full Text] [Related]
11. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
[TBL] [Abstract][Full Text] [Related]
12. Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia.
Azarova AM; Lin RK; Tsai YC; Liu LF; Lin CP; Lyu YL
Biochem Biophys Res Commun; 2010 Aug; 399(1):66-71. PubMed ID: 20638367
[TBL] [Abstract][Full Text] [Related]
13. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
Swan RL; Cowell IG; Austin CA
Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
[TBL] [Abstract][Full Text] [Related]
15. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
16. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
[TBL] [Abstract][Full Text] [Related]
17. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
[TBL] [Abstract][Full Text] [Related]
18. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
20. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions.
Leteurtre F; Fujimori A; Tanizawa A; Chhabra A; Mazumder A; Kohlhagen G; Nakano H; Pommier Y
J Biol Chem; 1994 Nov; 269(46):28702-7. PubMed ID: 7961822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]